Management of severe sepsis, an acute illness with high morbidity and mortality, suffers from the lack of effective biomarkers and largely empirical predictions of disease progression and therapeutic responses. We conducted a genome-wide association study using a large randomized clinical trial cohort to discover genetic biomarkers of response to therapy and prognosis utilizing novel approaches, including combination markers, to overcome limitations of single-marker analyses. Sepsis prognostic models were dominated by clinical variables with genetic markers less informative. In contrast, evidence for gene-gene interactions were identified for sepsis treatment responses with genetic biomarkers dominating models for predicting therapeutic responses, yielding candidates for replication in other cohorts.
Introduction
Severe sepsis, defined as sepsis associated with acute organ failure, is a leading cause of death worldwide. It accounts for up to 20% of all admissions to intensive care units with mortality rates reported in the range of 20-54% in the United States and Europe, and estimated in 2001 to result in 215 000 deaths annually in the United States. [1] [2] [3] The economic burden of severe sepsis is immense and likely to confer greater costs with aging populations. 1, 4 Although not completely understood, the pathophysiology of severe sepsis involves a highly complex interplay between the inflammatory and procoagulant response to infection. [5] [6] [7] [8] Drotrecogin alfa (activated) (DAA; Xigris, Eli Lilly and Company, Indianapolis, IN, USA) is a recombinant form of human activated protein C with anti-thrombotic, profibrinolytic, anti-inflammatory and cytoprotective properties. [9] [10] [11] The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, involving adult patients with severe sepsis, demonstrated an absolute risk reduction (ARR) in mortality of 6.1% at 28 days among patients treated with DAA as compared with placebo and a 19.4% reduction in the relative risk of death from all causes. 12 Apart from antibiotics, DAA was the only pharmaceutical specifically licensed for treatment of severe sepsis.
biomarkers to enhance the precision of clinical diagnosis and to identify patients who would benefit from particular therapies is important to improve patient outcomes and reduce mortality. 7, 14 Such markers could potentially predict DAA treatment response by identifying the patients most likely to benefit. Currently, clinical assessments of disease severity, such as the number of organ dysfunctions, presence of shock or severity scores (such as acute physiology and chronic health evaluation (APACHE) II), are used in DAA treatment decision-making.
Leveraging the advances in genotyping technology and interrogating the genome for polymorphisms is an important strategy for biomarker discovery. To date, more than 840 genome-wide association studies (GWAS) (compiled in the NHGRI online GWAS catalog 15 ) have been reported, 16 the majority investigating disease susceptibility with only a few investigating drug treatment responses or in acute and high severity illnesses such as sepsis. These reports have provided significant advances in our understanding of the pathophysiology of complex diseases such as Type 2 diabetes and heart disease. 17, 18 The large majority of GWAS studies, however, report only single-marker analysis (SMA) or multimarker analyses of those markers with marginal effects in SMA. Increasingly, concerns have been expressed that SMA may not be sufficient as this approach ignores gene-gene and gene-environmental interactions. 19 It is now recognized that such gene-gene interactions may be a key to understanding the biology of complex diseases, and understanding the genetic basis may prove elusive when only SMA approaches are employed. 20, 21 Challenges in testing for interactions include computational resource requirements and the immense number of statistical tests required. 21, 22 As the exhaustive searches required to detect gene-gene interactions poses a formidable and daunting challenge, a faster and more powerful two-stage conditional approach has been proposed by several groups. [23] [24] [25] [26] [27] [28] The highly complex nature of sepsis pathophysiology and treatment responses strongly suggest significant interactions between multiple gene products and environmental factors. 29 To address this hypothesis, we conducted analyses using single-marker marginal effects and established a methodology for assessing interactions on a genome-wide scale both for predictive (treatment response) and prognostic (28-day mortality) biomarkers in one of the largest cohorts of patients with severe sepsis studied to date. This cohort of patients from the PROWESS trial, 12 randomized to treatment with placebo or DAA, represent a relatively homogenous and uniquely well-phenotyped sample, in which markers are identified that may define subgroups with large differential treatment effects (drug response). We additionally sought to identify patient subgroups with greater susceptibility to death from severe sepsis, and to provide a clinically relevant contextual framework for the interpretation of the predictive genetic markers. We applied a novel integrated analytical approach to this cohort that includes: (1) establishing prespecified criteria considered clinically relevant, (2) balancing the effect size due to genetic and clinical markers, and the size of the patient subgroup identified by the biomarkers meeting these criteria, (3) objective and direct searching for two-and three-way interactions, (4) using permutation to assess global significance and (5) using a two-step conditional search, parallel computing and code optimization to drastically reduce computational time.
Materials and methods

Samples
PROWESS was a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of DAA in patients with severe sepsis, funded by Eli Lilly and Company. Eligible patients were enrolled from July 1998 to June 2000 (n ¼ 1690). The ethics board at each study center approved the original trial protocol and written consent was obtained from all participants or their authorized representatives. DNA collection was included in the trial with the intent of testing test for factor V polymorphism, and consultation with Bioethics committees determined that no additional consent was necessary for further genetic study on the anonymized samples. The entry criteria and clinical phenotyping for the PROWESS study have previously been reported. 12 A total of 1446 patient samples met quality control criteria (Supplementary Information) and were used for GWAS analyses.
Phenotype
The primary phenotype was 28-day all-cause mortality and the primary measure of efficacy was the ARR in the treatment group compared with placebo. The ARR was calculated as the difference in mortality rate between the placebo and the treatment group.
GWAS genotyping and quality control Genomic DNA was amplified directly from the FTA card using the GenomePlex whole genome amplification kit from Sigma-Aldrich (St Louis, MO, USA). Amplification samples were genotyped according to the manufacturer's protocol on the Ilumina Human1M-Duo BeadChip (Illumina, San Diego, CA, USA).
Stringent genetic data quality control was performed for each patient sample and for each genetic marker. [30] [31] [32] Details for quality control are described in the Supplementary Information. In total, 1446 out of 1568 patient samples were available for analyses (Supplementary Table 1) , and from all single-nucleotide polymorphisms (SNPs) (1 199 187) included in the initial analysis, 856 627 passed quality control criteria (Supplementary Table 2 ).
SMA using traditional association Detailed methodology for SMA using traditional association is described in the Supplementary Methods. Logistic regression was used for modeling, with appropriate covariates (such as age, APACHE II and so on). The P-value of the treatment * SNP interaction effect was estimated using the log-likelihood ratio test.
The entire PROWESS cohort (excluding patients according to quality control criteria), regardless of reported ethnicity, Treatment responses in severe sepsis M Man et al was analyzed together to maximize sample size and statistical power. Population stratification was assessed using multidimensional scaling, in which proximity in the lower dimensional space indicates a similarity in genetic makeup. Only SNPs on autosomes were included in the multidimensional scaling analysis. Population stratification was adjusted by incorporating the first few principle components of the multidimensional scaling into the logistic model.
Using a two-step conditional multimarker search in GWAS for treatment response markers The primary objective was to identify a patient subgroup with a differential treatment response. To be selected, markers needed to define a subgroup that contained at least 20% of the PROWESS population with an ARR of 412.5%. An ARR of 12.5% was chosen as it was close to the 13% ARR identified by the clinical marker of APACHE score X25, and it was felt that to be of potential value, a genetic marker would need to perform well, if not better, than an accepted clinical marker. SNPs as well as clinical and protein markers (Supplementary Table 3 ) were used to define patient subgroups. A two-step method was used to identify markers that defined subgroups with better differential treatment response in a sizable number of subjects [23] [24] [25] 28 (Supplementary Methods). ARRs instead of P-values were used as selection criteria for testable hypothesis.
Additional analyses were completed for each of the 100 highest-ranking combination markers (CM): logistic regression treatment interaction analysis was completed; a loglikelihood ratio test was used to assess the contribution of the third marker for each of the 100 highest-ranking CMs; a Cox model (survival timeBage þ prapache (pre-infusion APACHE II score) þ therapy) was used to model survival time by CM genotype and statistical significance (Supplementary Methods), with Kaplan-Meier survival curves constructed; and pair-wise linkage analysis 33, 34 (Supplementary Methods). Permutation runs were used to establish a reference distribution for the top markers identified from GWAS for treatment response and prognostic markers (Supplementary Methods).
GWAS for prognostic markers
The markers for risk of 28-day mortality in the placebo population of PROWESS were identified using a two-step multimarker search. Top markers were selected based on the LOESS (local polynomial regression fitting) method that balanced the trade-off between risk (28-day mortality rate in the placebo group) and subgroup size defined by the marker (Supplementary Methods).
Computing A Linux computer cluster (IBM System Cluster 1350, about 250 nodes and 1000 central processing unit cores, automated job scheduling and balancing) was used for all parallel computing.
Results
Study population
The study population included patients enrolled in the PROWESS trial 12 (Study code F1K-MC-EVAD; PROWESS predated registration requirements on ClinicalTrials.gov) with clinical data, and genetic data passing quality control (n ¼ 1446) (Supplementary Information).
GWAS for treatment response markers
To identify markers delineating a population with improved response to DAA, the association of 28-day all-cause mortality with 1 199 187 SNPs, genotyped utilizing the Illumina Human1M-Duo BeadChip according to the manufacturer's protocol (Illumina), was completed. In addition, we also included 283 markers (from 18 candidate genes) and 33 clinical variables in the search (Supplementary Table 3 ). As multiple mechanisms are likely involved, both singlemarker and two-and three-CM analyses were completed, representing an agnostic view of the marker's contribution to severe sepsis. The single-marker analyses utilized traditional association methodology (Supplementary Methods) that included logistic regression to identify SNP-by-treatment interaction and yielded few markers with a strong signal (SNPs with Po1 Â 10 À5 ) (Supplementary Table 4 ). One marker, rs17513961 in the 5 0 untranslated region of LOC222052 (located near the insulin-like growth factor I (IGF1)-binding protein gene), met the threshold for genome-wide significance (Po5 Â 10 À7 ). 30 Figure 1 shows a representative Manhattan plot highlighting the significant findings, with few points above the line expected by chance ( Supplementary Figures 1 and 2 for further Manhattan plots and quantile-quantile plots 35 ). Figure 1) . GWAS ¼ genome-wide association study.
Treatment responses in severe sepsis
The two-and three-CM analyses employed a prespecified cut-off for potentially informative markers including both an ARR and percentage of the population considered clinically meaningful (ARR 412.5% and subgroup size 420%). The analytical methodology allowed a comprehensive search of all clinical and/or genetic markers without prespecifying a mode of inheritance (Supplementary Methods). In all, 453 three-marker combinations were identified (identified as top markers using LOESS). The top 20 of these three-CMs are presented in Table 1 (Supplementary Table 5 for the top 100 three-CMs and Supplementary Table 6 for the top 100 single-markers from the multimarker search). The ARR for the top 100 CMs ranges from 17.9% (confidence interval, 12.5-23.3) in a subgroup comprising 69% of the PROWESS population to 42.9% (confidence interval, 33.5-52.3) in a smaller subgroup of PROWESS (21%). The ARR for these CMs is larger than the 6.1% observed for the entire PROWESS study population, or the 7.4% if the percentage of sepsis patients with two or more organ failures is considered (European DAA-indicated population), or the 13% for sepsis patients at high risk of death (for example, APACHE II score X25; the US DAA-indicated population). The top 100 CMs did not contain any clinical markers, only genetic markers, and were comprised of 69 unique SNPs in 54 genes. Analyses to assess the correlation among those top 69 SNPs were completed (Supplementary Methods) using multidimensional scaling to visualize the correlation, with top CMs appearing to define subgroups of patients in six clusters (Supplementary Figure 3) . The highest-ranked three-CMs included rs7725278 in the intergenic region near the dopamine receptor D1 (DRD1), rs2256527 in the intergenic region near LOC391273 and rs10910651 in an intron of pecanex-like 2 (PCNXL2). None of the SNPs comprising these top CMs figured in the top 10 of the single-marker results.
Several additional analyses were employed to understand the relevance of these findings. Logistic regression associating the top 100 CMs identified with differential responses to DAA treatment (28-day all-cause mortality) assigned P-values ranging from 5.3e-13 to 1.3e-20. Survival analyses were also completed, and for the top CM identified, 26% of the patients had a genotype associated with a favorable treatment response with a 41.7% ARR (Figure 2 ). Although these P-values appear low, millions of combinations are tested, when looking for interactions, and multiplicity is a significant issue. There is no current standard methodology to adjust for multiple testing for two-and three-way interaction, therefore, to put the results in the context of what might be observed due to chance alone, permutation analyses were completed. 26, 27 In all, 1000 permutations were completed to form a reference distribution, with LOESS employed to estimate a 95% upper confidence bound on marker significance (Supplementary Methods). The CMs residing above the smoothed 95% line represent the top combinations from the top 20 CMs contained in Table 1 ( Figure 3) . Each of these combinations include SNPs, which reside in proximity to the DRD1 gene.
GWAS for prognostic markers
A second GWAS analysis was conducted on the subset of patients in the PROWESS study 12 who received placebo to help identify prognostic clinical or genetic markers for Table 1 Twenty highest-ranked three-SNP genetic combination markers from the GWAS for treatment response markers Abbreviations: ARR, absolute risk reduction; GWAS, genome-wide association study; ID, combination marker identification (based on ranking using the LOESS method); LOESS, local polynomial regression fitting; N, subgroup size; SNP, single nucleotide polymorphism.
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28-day all-cause mortality in patients diagnosed with severe sepsis. The single-marker analyses yielded five markers with a strong signal for outcome with sepsis, with each of these markers reflecting clinical indices. These markers include: creatinine clearance (estimated), baseline APACHE II score X25, age 4th quartile (X74.1 years), age 3rd and 4th quartiles (X63.6 years) and baseline protein C activity 1st quartile (activity p32%). Apart from protein C, these reflect patients' age or have age as a component of the score calculation. When completing the multimarker analyses, the top markers from the two-marker and three-marker analyses include the top clinical markers, which appear to be the primary drivers of the prognostic effect ( Figure 4) . As with the GWAS for treatment response, permutation analyses were completed. In the first step of the multimarker search, only the top 5 clinical markers clearly differentiate from the reference LOESS line (Figure 5c ) with approximately 20 markers slightly above (Supplementary Table 7 ). In the analyses of the two-and three-CM results, CMs falling above the LOESS-smoothed line were driven by the same clinical markers observed with the first step of the multimarker search (one-marker) and not by a clinical marker and genetic interaction (Figures 5a and b) .
Owing to the vast computational resource requirements and the lack of an efficient search method, permutations on a genome-wide scale are often not feasible for many investigators. We evaluated the number of permutation runs required to provide a small standard deviation. Our results indicate that a smaller number of permutation runs may provide a reasonable confidence interval greatly reducing the required computing time (Supplementary Figure 4) . For example, this could reduce the time from 4 months to 2 weeks, making this type of permutation analyses more feasible.
Discussion
The results of this study represent the largest severe sepsis population with prospectively collected clinical data and randomized drug treatment (DAA) for which genome-wide analyses have been completed. Because of the unique characteristics of this cohort, it was possible to investigate In subjects with the þ / þ combination genotype, treatment with DAA was associated with a significantly higher survival rate than placebo treatment (P ¼ 2.2e-16). For the top CM, the þ / þ genotype represents 26% of the PROWESS population, and is comprised of rs7725278, rs2256527 and rs10910651. P-values are reported as two-sided and were determined by Cox regression (adjusted for age and treatment). CM ¼ combination marker, DAA ¼ drotrecogin alfa (activated), N ¼ subgroup size, PROWESS ¼ Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis trial. Table 1 , can be seen slightly above the smoothed 95% line. CM ¼ combination marker, GWAS ¼ genome-wide association study, LOESS ¼ local polynomial regression fitting, N ¼ subgroup size.
Treatment responses in severe sepsis M Man et al both markers prognostic for sepsis as well as markers predictive of treatment response. In addition, the novel analytical approaches employed allowed identification of epistatic interaction between markers and marker-defined patient subgroups with a significant improvement over the current treatment risk/benefit profile: the marker-defined patient subgroups representing 420% of the sepsis population with an ARR between 17.9% and 42.9%, as compared with the 6.1% ARR conferred for the population as a whole by DAA treatment alone. The majority of markers identified in the multimarker approach were not those that were significant in the single-marker analyses. These findings provide further evidence that complex disease and treatment response are multifactorial, likely needing multiple biomarkers to identify a significant amount of the variability in response, highlighting the need for the analytical approaches outlined.
The approach reported here, has utility for identifying novel markers from the many existing GWAS data sets. 16 The derivation of variables based on all the possible combinations of genotype and clinical markers allows for an objective and comprehensive assessment. The computational time, often a limitation of multimarker analyses, can be reduced by applying both parallel computing and a conditional two-stage approach. Applying the LOESS criteria at the two-stage interaction reduces the computational requirements, while still ensuring high power to detect a moderate interaction effect. The exhaustive search would have been computationally prohibitive but was reduced to approximately 3 weeks utilizing 1000 central processing units by employing parallel computing, a conditional two-stage approach and LOESS methodology. In order to implement the permutation strategy encompassing 1000 runs, further reduction in computing time was achieved by converting the majority of the R code to a program written in C, resulting in a single run taking 2 h. The remaining R code was for aggregating results and carrying out LOESS. The overall gain in computing efficiency makes it possible to conduct searches for gene-gene interactions and also provides a meaningful reference for overall significance using permutation.
When millions of nonindependent combinations are assessed, such as in a multimarker search for epistasis, P-values and effect size alone may lead to a high false positive rate, an overestimate of effect size and the identification of very small patient subgroups. Although results that pertain to an individual or very small patient subgroup are biologically interesting, unless a significant percentage of the population is identified by the marker, it is difficult to assess in further trials and develop diagnostics to guide therapy. The LOESS method allows for balancing two variables to search for markers meeting preestablished criteria for clinical relevance. Additionally, the inclusion of both markers used currently in clinical practice and genetic markers allowed for the clinical markers to act as a reference in interpreting the genetic results. Furthermore, permutation testing is needed because small P-values and large effect size may not provide adequate protection against false positive findings. 26 However, permutation testing of millions of possible combinations is often again limited by computational resources. The data presented herein demonstrate that a reasonable confidence interval can be established following only 100 permutations rather than the typically recommended 41000, greatly reducing the required computational time. Thus, the approach presented is a viable methodology to identify epistatic interactions on a large scale.
Several genetic markers that met the prespecified criteria for clinical relevance for treatment response are biologically interesting but need to be replicated and confirmed in additional studies. The DRD1 is a member of the G proteincoupled receptor superfamily and is adenylate cyclasestimulating. 36 DRD1 is involved in the control of vascular tone, 37 a key component of shock, the presence of which is a major determinant of outcome in severe sepsis. Additionally, DRD1 influences vascular hemodynamics and renal sodium transport, and polymorphisms in the genes involved in the dopaminergic system have now been implicated in the susceptibility to hypertension 38, 39 and renal dysfunction. 40 As acute renal failure may accompany sepsis due to acute tubular necrosis and is associated with both morbidity and mortality, the DRD1 gene could potentially contribute to the integrated biological response to sepsis. The IGF1-binding protein complex has been shown to modulate the sepsis-induced inhibition of protein synthesis in skeletal muscle, 41 and circulating IGF1-binding protein increases significantly and selectively in response to systemic endotoxin in an ovine model of sepsis, resulting in alternations in growth hormone and glucose metabolism. 42 IGF1 is one of the most potent natural activators of the Akt (a serine/ threonine protein kinase) signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. 43 Akt signaling is important in the anti-apoptotic effects on endothelial cell survival, so low levels of IGF may predispose to endothelial cell damage or apoptosis in severe sepsis. Although further investigation of the genes identified in this exploratory study require replication in additional cohorts to understand the true effect size, these results provide interesting candidates that warrant further investigation. Even though this cohort represents the largest placebocontrolled study allowing for the search for predictive and prognostic markers, the prognostic marker search included only 700 patients in the placebo arm. In contrast to the treatment results, the examination of prognostic factors in sepsis yielded fewer interesting genetic candidates. The wellestablished clinical parameters, such as age and kidney function, and the hypothesized protein C marker 44, 45 were the top candidates. Despite this, several of the genetic markers identified in the multimarker analyses warrant investigation in other studies. Intriguingly, previously published SNPs (that relied on a candidate gene approach), which have been proposed of having an association with clinical outcome in severe sepsis, [46] [47] [48] [49] were not identified as being prognostic in this analysis. The lack of significant genetic prognostic markers may simply reflect the sample size of the cohort. Although one of the largest cohorts is available with characterized sepsis, the complexity of the disease and the response prodrome are likely the result of many biological processes and multiple genes of small effect. The current sample size may not provide sufficient power to detect genetic markers, and although of biologic interest, did not meet our prespecified criteria for clinical relevance (Supplementary Methods). Another contributor could be that the clinical definition of severe sepsis may include a number of clinically distinct illnesses, for example, community-acquired pneumonia or peritonitis. As with other complex traits, there appears to be many genes of marginal to small effect that are difficult to understand with a single study and the results presented herein, therefore, need further replication. In addition, fitness traits generally have low heritability with environment Â genetic interaction effects driving the response; often representative of posttranscriptional events, these and more complex structural changes in DNA would not be identified in a GWAS.
In conclusion, we applied a novel approach of mining whole-genome scan data to better understand the complex biology and treatment response in severe sepsis. We included both clinical and genetic markers in the analyses, with clinical markers acting as a 'reference' to help interpretation of genetic results. A multimarker approach was employed, not only for testing additive effects but also true epistatic interactions, and we balanced the results between effect size and patient subgroup to provide results in context of a clinically relevant subgroup. Permutation runs were performed in order to estimate a reference distribution for the top markers identified, which allowed us to overcome some of the recognized current difficulties with GWAS. These novel approaches have led to the affirmation of clinical variables as important prognostic markers and the Treatment responses in severe sepsis possible identification of epistatic interactions in the drug response of severe sepsis.
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